Takeda Entyvio trial shows disease clearance cuts UC complication risk

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. LRCX
7. MRK
8. LVS
9. SAP
10. CSX

Go back to Takeda Entyvio trial shows disease clearance cuts UC complication risk

First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication

October 19, 2026 5:30 AM EDT

More than half of ENTYVIO patients who met their assigned treatment target reached disease clearance (composite of corticosteroid-free symptomatic, endoscopic and histologic remission) at Week 16 VERDICT is the first trial to provide macroscopic and microscopic evidence of intestinal tissue repair associated with disease clearance in largely bio-naïve patients treated with an advanced therapy

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda... More